STOCK TITAN

Panbela Therapeutics, Inc. - $PBLA STOCK NEWS

Welcome to our dedicated page for Panbela Therapeutics news (Ticker: $PBLA), a resource for investors and traders seeking the latest updates and insights on Panbela Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Panbela Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Panbela Therapeutics's position in the market.

Rhea-AI Summary
Panbela Therapeutics announces European patent for novel process to produce SBP-101, reducing synthetic steps from 17 to 6. Patent valid until 2039. Expands patent portfolio and supports global clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
Rhea-AI Summary
Panbela Therapeutics, Inc. (Nasdaq: PBLA) provides a business update and reports financial results for Q2 2023. Key highlights include partnerships, clinical trial progress, financial/business updates, and communication of science. The company closed a registered public offering for $8.5 million and regained the North American rights to develop and commercialize Flynpovi tm. They also opened enrollment in the ASPIRE trial for pancreatic cancer and passed pre-planned futility analysis in the PACES Phase III trial for colorectal cancer. The company expects to deliver value creation by advancing its pipeline and executing against upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
conferences earnings
-
Rhea-AI Summary
Panbela Therapeutics, Inc. has divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds. The agreement entitles Panbela to receive up to approximately $9.5 million non-dilutive funding. US WorldMeds will further develop eflornithine for the treatment of neuroblastoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Panbela Therapeutics, Inc. announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III ASPIRE clinical trial for patients with metastatic pancreatic ductal adenocarcinoma has recommended the study to continue without modification. The trial is evaluating ivospemin in combination with gemcitabine and nab-Paclitaxel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.48%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
Panbela Therapeutics, Inc.

Nasdaq:PBLA

PBLA Rankings

PBLA Stock Data

2.86M
4.85M
0%
0.16%
3.07%
Biotechnology
Healthcare
Link
United States of America
Waconia